1. Introduction {#sec1-cancers-11-00493}
===============

Head and neck cancer (HNC) includes a set of diverse neoplasms located in the lips, oral cavity, pharynx, larynx, salivary glands and thyroid glands, among others. Most HNC belong to the squamous cell carcinomas group \[[@B1-cancers-11-00493]\]. Approximately 600,000 new cases are diagnosed per year, being the sixth cancer type on incidence worldwide. Treatment of early stages includes surgery and/or radiotherapy, while locally advanced tumours are also treated with chemotherapy and biological therapies \[[@B2-cancers-11-00493]\]. Only 40--50% of patients survive for five years \[[@B3-cancers-11-00493]\] causing an annual death rate of 271,000 patients \[[@B4-cancers-11-00493],[@B5-cancers-11-00493]\].

The oncogenic transformation of normal mucosa into a squamous cell carcinoma of the head and neck is a multifactorial process, associated with a variety of risk factors. At least 75% of head and neck squamous cell carcinomas (HNSCC) are attributable to the combination of cigarette smoking and alcohol drinking, the most classic carcinogens \[[@B6-cancers-11-00493],[@B7-cancers-11-00493]\]. Diverse epidemiological studies have also revealed the existence of other environmental and genetic related factors. Similar to other tumours, viral aetiology has shown an implication in HNSCC development, predominating Epstein--Barr virus (EBV) infection in nasopharynx, and human papillomavirus (HPV), mainly subtype 16, in oral cavity and oropharyngeal tumours \[[@B8-cancers-11-00493]\]. The carcinogenesis process triggered by viral infection defines a different entity to that caused by tobacco and alcohol \[[@B8-cancers-11-00493]\], allowing HNSCC classification into two main prognostic and therapeutic groups, in which HPV-negative tumours are associated with an aggressive course and a worse prognosis than HPV positive ones \[[@B9-cancers-11-00493],[@B10-cancers-11-00493]\].

Despite the defined role of environmental factors, there is also evidence of familial aggregation and increased cancer risk amongst HNSCC relatives \[[@B11-cancers-11-00493]\], suggesting the existence of genetic predisposition factors \[[@B12-cancers-11-00493]\]. However, not all individuals exposed to these carcinogens will develop the disease. In this context, the identification of genetic variants in important signaling pathways could help to define tumour susceptibility, as well as differences in treatment response and toxicity. HNSCC carcinogenesis involves different pathways: carcinogen metabolism, DNA repair, cell cycle, immunity and inflammation \[[@B13-cancers-11-00493],[@B14-cancers-11-00493],[@B15-cancers-11-00493]\]. Single nucleotide polymorphism (SNP) is the most abundant form of genetic variation, becoming an ideal genetic susceptibility marker \[[@B1-cancers-11-00493]\].

In this study, we aimed to examine polymorphisms in genes involved in relevant oncogenic pathways within a paired population of cases and controls in a large Spanish population.

2. Results {#sec2-cancers-11-00493}
==========

2.1. Characteristics of Groups {#sec2dot1-cancers-11-00493}
------------------------------

After the application of the propensity score method 126 larynx, 100 pharynx and 70 oral cavity squamous cell carcinomas were totally paired with their specific control group. The analysis by location did not show any statistically significant difference between sex, age, tobacco and alcohol intake with respect to the control group ([Table 1](#cancers-11-00493-t001){ref-type="table"}). Only age was statistically different (*p* \< 0.05) between laryngeal tumour and control group, so this variable was included in the logistic regression as an adjustment variable.

2.2. Candidate Gene Association Study {#sec2dot2-cancers-11-00493}
-------------------------------------

Nine out of twenty-nine selected SNPs showed a statistically significant result in the distribution between the patient and control groups.

Beginning with DNA repair genes, less common genotypes in *ERCC1* rs11615 (*p* = 0.011, OR = 0.288 (CI 95% = 0.110--0.751) in a recessive model) and *ERCC2* rs13181 (*p* = 0.046, OR = 0.375 (0.143--0.982) in a codominant model) were associated with a lower risk of laryngeal cancer ([Table 2](#cancers-11-00493-t002){ref-type="table"} and [Table S2](#app1-cancers-11-00493){ref-type="app"}).

Secondly, pro-inflammatory *IL6* rs1800795 polymorphism was related to a higher risk of laryngeal cancer in a dominant model (*p* = 0.002, OR = 2.394 (1.376--4.163)) ([Table 2](#cancers-11-00493-t002){ref-type="table"} and [Table S2](#app1-cancers-11-00493){ref-type="app"}), similar to the association found in CG+GG variants with increased oral cavity susceptibility (*p* = 0.018, OR = 2.265 (1.148--4.467)). Moreover, another SNP in the inflammatory gene *IL2* rs2069762 G variant was associated with a lower risk of oral cavity cancer (GG *p* = 0.039, OR = 0.300 (0.096--0.940)) ([Table 3](#cancers-11-00493-t003){ref-type="table"} and [Table S3](#app1-cancers-11-00493){ref-type="app"}).

In relation to apoptotic genes, three SNPs in apoptotic genes were associated with different susceptibility in all HNSCC locations. The *TP53* rs1042522 mutant allele in the recessive model was associated with a decreased risk of developing laryngeal cancer (*p* = 0.002, OR = 0.286 (0.119--0.607)) (see [Table 2](#cancers-11-00493-t002){ref-type="table"} and [Table S2](#app1-cancers-11-00493){ref-type="app"}); and pharyngeal cancer (*p* = 0.001, OR = 0.124 (0.035--0.476)) (see [Table 4](#cancers-11-00493-t004){ref-type="table"} and [Table S4](#app1-cancers-11-00493){ref-type="app"}). Further, variant allele in *MDM2* rs2279744 was associated with higher risk of laryngeal cancer (*p* = 0.029 OR = 2.413 (1.094--5.323)) in a recessive model ([Table 2](#cancers-11-00493-t002){ref-type="table"} and [Table S2](#app1-cancers-11-00493){ref-type="app"}). Meanwhile CA+AA genotypes in *BCL2* rs2279115 were related with a higher risk of developing oral carcinoma (*p* = 0.010, OR = 2.753 (1.273--5.952)) in a dominant model ([Table 3](#cancers-11-00493-t003){ref-type="table"} and [Table S3](#app1-cancers-11-00493){ref-type="app"}).

Finally, an association between antioxidative SNPs and laryngeal and pharyngeal cancer was found. Variant genotypes rs1303586 GA+AA and rs2706110 CT+TT, both in the *NRF2* gene, were associated with a lower risk of laryngeal carcinoma (*p* = 0.035, OR = 0.478 (0.240--0.949) and *p* = 0.518, OR = 0.518 (0.299--0.900), respectively) ([Table 2](#cancers-11-00493-t002){ref-type="table"} and [Table S2](#app1-cancers-11-00493){ref-type="app"}). On the other hand, in pharyngeal cancer, only *NRF2* rs2706110 less common allele genotypes CC+CT were related with a lower risk of developing pharyngeal carcinoma (*p* = 0.043, OR = 0.552 (0.311--0.982)) ([Table 4](#cancers-11-00493-t004){ref-type="table"} and [Table S4](#app1-cancers-11-00493){ref-type="app"}).

3. Discussion {#sec3-cancers-11-00493}
=============

Not all individuals exposed to the same classical carcinogens (tobacco and alcohol) develop HNSCC. Although several susceptibility studies have identified SNPs in carcinogenesis-related pathways, their results are controversial due to an inadequate control group. In this multicentre case-control study, we examined the association between some polymorphisms and HNSCC susceptibility in a Spanish cohort with a control group totally paired by their risk factors, avoiding confounder variables.

Analysis of laryngeal squamous cell carcinoma showed an association with lower susceptibility risk in *ERCC1* rs11615 and *ERCC2* rs13181 SNPs. Indeed, these genotypes have also been associated with a better response and longer survival in patients treated with platinum \[[@B16-cancers-11-00493]\] due to an increase in DNA damage and induction of cell death, providing a potential explanation of our results.

Inflammation has been considered an important factor in the pathogenesis of human cancer \[[@B17-cancers-11-00493],[@B18-cancers-11-00493],[@B19-cancers-11-00493]\], with a special interest in the context of oral cancer \[[@B20-cancers-11-00493],[@B21-cancers-11-00493]\]. The rs1800795 -174C variant in the promoter of the *IL6* gene is related to a lower level of serum proteins, while -174G corresponds to a higher expression, increasing the inflammatory response \[[@B22-cancers-11-00493]\]. Our study shows an association between the G allele and a higher risk of developing laryngeal and oral tumours, probably related to the carcinogenesis induced by inflammation. Moreover, cytokine *IL-2* plays a role in the proliferation of activated T-lymphocytes and in the activation of phagocytes. The G allele in the -330G\>T (rs2069762) SNP increases the *IL2* gene expression, whereas the T allele is associated with a decreased *IL2* expression skewing the Th1/Th2 immune balance towards Th2 \[[@B23-cancers-11-00493]\]. In our study, the *IL2* rs2069762 GG genotype was associated with lower oral cavity risk, in contrast to previous reported associations \[[@B23-cancers-11-00493]\] in another tumour types with different risk factors and ethnic background. This result could be explained by the main role of IL-2 in the elimination of self-reactive cells \[[@B24-cancers-11-00493]\], decreasing the antitumour response produced by the immune system.

Mdm2 attenuates the tumour suppressor protein p53 through proteasomal degradation via ubiquitinylation, while p53 induces *MDM2* transcription in response to genotoxic stress \[[@B25-cancers-11-00493]\]. SNP rs2279744 -410T\>G, located in the P2 promoter, increases *MDM2* expression by improving the binding affinity with the Sp1 transcription factor, attenuating the *TP53* suppressor pathway \[[@B26-cancers-11-00493]\]. Our data is in line with previous reports \[[@B27-cancers-11-00493]\], demonstrating a higher risk of laryngeal cancer in those patients with the GG genotype.

The polymorphism c.215C\>G (Pro72Arg) in the exon 4 of *TP53* is found in an essential domain in the apoptotic response and carcinogenesis inhibition. The arginine allele is a more powerful apoptotic inductor than the proline one \[[@B28-cancers-11-00493],[@B29-cancers-11-00493]\]. Some studies have associated the Pro72Arg polymorphism with an increased risk of developing gastric, oesophageal and bladder cancer \[[@B30-cancers-11-00493],[@B31-cancers-11-00493]\], but little data has been reported regarding HNSCC \[[@B32-cancers-11-00493],[@B33-cancers-11-00493]\]. Our results show a lower susceptibility of developing pharyngeal and laryngeal cancer for the variant alleles. While this could be due to its association with longer survival or modifications at cell cycle and the maintenance of DNA integrity \[[@B28-cancers-11-00493],[@B34-cancers-11-00493]\], we have also shown this protective association in stroke \[[@B35-cancers-11-00493]\] and other ischemic processes (Cruz-González et al., data not published), possibly being a case selection bias.

In addition, we found a statistically significant association between the anti-apoptotic gene BCL2 SNP and oral cavity cancer susceptibility. *BCL2*-938C\>A (rs2279115) polymorphism is found in P2 gene promoter, acting as a negative regulator element, decreasing P1 promoter activity \[[@B36-cancers-11-00493]\]. The presence of C allele highly reduces the activity of P1 and Bcl-2 protein expression, increasing apoptosis. Our results showed similar results to those reported in breast cancer and acute myeloid leukaemia \[[@B37-cancers-11-00493]\] where the presence of the A allele (CA+AA) increased tumour susceptibility due to an anti-apoptotic effect \[[@B38-cancers-11-00493]\].

Finally, *NFE2L2* gene codes for a transcription factor protein (Nrf2) that induce many antioxidative genes under oxidative stress. SNPs in this gene have been associated with cancer risk \[[@B39-cancers-11-00493]\]. In our series, *NFE2L2* rs2706110 and rs1303586 less common genotypes were linked with lower risk of developing laryngeal cancer, while in pharyngeal cancer, only rs1303586 was associated. Functional analyses of these SNPs have not yet been described but our hypothesis is that these changes could increase antioxidative gene induction under stress produced at high levels in HNSCC by tobacco and alcohol consumption.

4. Material and Methods {#sec4-cancers-11-00493}
=======================

4.1. Study Population {#sec4dot1-cancers-11-00493}
---------------------

TTCC-2010-05 was an observational multicentre study conducted in 19 Spanish centres, all of them belonging to the Spanish Head and Neck Cancer Treatment Group (TTCC) coordinated by the Medical Oncology Department of the University Hospital of Salamanca, between January 2012 and December 2014. Epidemiological and clinicopathological details have been previously described \[[@B40-cancers-11-00493]\].

Cases inclusion criterion was: histologically confirmed HPV-negative HNSCC patients from larynx, oro/hypopharynx and oral cavity carcinomas. They were recruited in Oncology, Radiotherapy and Otorhinolaryngology departments. Controls were follow-up individuals with minor issues and without a tumour history and paired by age, sex, smoking and alcoholic habit with HNSCC cases. They were captured in Pneumology, Radiotherapy, Otorhinolaryngology and Internal Medicine departments. Only the Spanish population were permitted, avoiding ethnicity bias.

Considering HNSCC incidence in Spain, 10% of possible losses and duration of the study, initial calculations of recruitment were of 440 individuals in patient and control group. Finally, a total of 459 patients and 259 controls were included.

In this study, the variables were polymorphisms in oncogenes, tumour suppressor genes, genes implicated in DNA reparation, inflammation, carcinogen metabolism and apoptosis, together with some risk factors collected in the socio-demographic (6 questions) and the data informed by patients (19 questions) questionnaires. The information of both questionnaires was collected via auto-application, being supervised by the members of the research team. Clinicopathologic data, response and specific toxicity to treatment were collected by oncologists in the case report form questionnaire (CRF).

The study was approved by the University Hospital of Salamanca and the local ethics committees in accordance with the 1964 Helsinki declaration and its later amendments. All participants were previously informed and signed the provided informed consent. All data were treated with the security measures established in compliance with the Protection of Personal Data Organic Law 15/1999, December 13, and safe-keeping by the University Hospital of Salamanca in its specific hospital server. This study was supported by the Ministry of Economy and Competitiveness under the identification code PI11/0059.

4.2. Selection of Polymorphism {#sec4dot2-cancers-11-00493}
------------------------------

Candidate SNPs selection was done according to at least two of the following criteria: \>5% allele frequency in Caucasian/European population, previously defined association with HNSCC susceptibility and earlier related different response or toxicity to chemotherapy or radiotherapy. At the initial stages of the project design, a huge search was performed in available databases using keywords such as SNPs, susceptibility, HNSCC, response and toxicity, selecting only those with statistically significant results in other populations \[[@B14-cancers-11-00493],[@B15-cancers-11-00493],[@B32-cancers-11-00493],[@B41-cancers-11-00493],[@B42-cancers-11-00493],[@B43-cancers-11-00493]\]. SNPs with some published evidence of functionality were preferably selected [Table 5](#cancers-11-00493-t005){ref-type="table"}.

4.3. DNA Isolation and Genotyping {#sec4dot3-cancers-11-00493}
---------------------------------

DNA was extracted from peripheral blood leukocytes using the phenol-chloroform method. Genotyping was performed using the TaqMan^®^ Allelic Discrimination Assay \[[@B44-cancers-11-00493]\] (Applied Biosystems, Foster, CA, USA) in those SNPs where the probes were available. A concentration of 40 ng/μL of DNA samples were added to 6.25 μL of Taqman^®^ Universal PCR Master Mix and it was combined with specific forward and reverse primers, and allele-specific VIC (allele 1) and FAM (allele 2) labelled probes. The assay was performed in a 96 well plate and the detection was measured in the Step One Plus Real-Time PCR System Thermal Cycling Block (Applied Biosystems, Foster, CA, USA). Negative and positive controls were always added. A total of 5% of random samples were re-genotyped to ensure the reproducibility.

In those candidate SNPs in which TaqMan® probes were not available, genotyping was analysed using polymerase chain reaction---restriction fragment length polymorphism (PCR-RFLP). Specific oligonucleotides were designed to amplify the polymorphic sequences and digestion was made via the specific restriction enzymes. The PCR products were run on 3% Syber-safe stained agarose gel and visualized under UV light. GSTT1 and GSTM1 null/present SNPs were analysed using PCR with β-actin as an endogenous control. Finally, for KRAS-LC6 rs61764370, a custom probe was specifically designed. Sequences and type of assays are shown in [Table S1](#app1-cancers-11-00493){ref-type="app"}.

4.4. Statistical Analysis {#sec4dot4-cancers-11-00493}
-------------------------

The statistical analysis to associate the relation between the different clinical and molecular variables was analysed using cross tabs and the χ^2^ test of Pearson. The odds ratios (OR) and 95% confidence intervals were calculated using logistic regression analysis. The quantitative variable distribution was analysed using the ANOVA test in those examples where the sample followed a parametric distribution (*p* \> 0.05 in Levene's test), while in those with a non-parametric distribution, a Mann--Whitney *U* test was applied. Hardy--Weinberg equilibrium (HWE) was tested in a control population using a χ^2^ test. Statistically significant differences were considered to exist when the two-sided *p*-value was \<0.05. Only TP53 rs1042522 and APEX rs1130409 were in disequilibrium (*p*HWE \< 0.05).

Because of the lower inclusion of matched controls, the statistical analysis was realised when matching the group via the propensity score method (PS). This allowed us to equate groups in a cohort study through a logistic regression introducing the confounders as predictive variables \[[@B45-cancers-11-00493],[@B46-cancers-11-00493],[@B47-cancers-11-00493]\]. Groups were matched according to: packs per year consumed (PPY): no smokers, \<20PPY and \>20PPY, standard unit of alcohol per week (SDU/week): \<14SDU/week and \>14SDU/week, and sex. Quantitative age was not included in the PS and it was introduced in the logistic regression as adjustment variable only in laryngeal cancer where the age between both groups was statistically significant.

These analyses were performed with the statistical software SPSS v.21.0 (IBM-SPSS Inc., Chicago, IL, USA).

5. Conclusions {#sec5-cancers-11-00493}
==============

This study shows the association between several polymorphisms in genes involved in DNA repair, inflammation, antioxidative and apoptotic pathways with susceptibility to developing HPV-negative HNSCC. The characteristics of the control group positively indicates that these results are caused by the genetic background, avoiding confounder variables. Likewise, the differences found in this association study according to the location corroborate the heterogeneity in these tumours included under the same term of head and neck squamous cell carcinoma. It is important to mention that this study could provide evidence to define the consideration of different genetic entities within HNSCC and the necessity of using a matched control population by their risk factors in future case-control studies. Larger studies should be performed and would be necessary to confirm these results.

The authors thank the patients who have participated in this study and their families. Moreover, we are grateful for the great effort from all the collaborators of the Spanish Head and Neck Cancer Cooperative Group (TTCC) that are not included in this manuscript and the support from the Institute of Biomedical Research of Salamanca (IBSAL).

The following are available online at <https://www.mdpi.com/2072-6694/11/4/493/s1>, Table S1: Primer sequences and genotyping assays in those SNPs defined in [Table 5](#cancers-11-00493-t005){ref-type="table"} without specific TaqMan^®^ probes, Table S2: Distribution between studied SNPs in different genes in laryngeal tumours (Ca) and controls (Co)\*, Table S3: Distribution between studied SNPs in different genes in tumours from oral cavity (Ca) and controls (Co), Table S4: Distribution between studied SNPs in different genes in pharyngeal tumours (Ca) and controls (Co).
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cancers-11-00493-t001_Table 1

###### 

Descriptive characteristics and risk factors of paired patients by location in the case-control study. Data after the propensity score method corroborate the equality between the different locations with their specific controls, except for age in laryngeal tumours (introduced as an adjustment variable in the logistic regression).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group Comparison       LARYNX\         CONTROL\         *p*-Value   PHARYNX\       CONTROL\         *p*-Value   ORAL CAVITY\     CONTROL\       *p*-Value                                     
                         *N* = 126       *N* = 126                    *N* = 100      *N* = 100                    *N* = 70         *N* = 70                                                     
  ---------------------- --------------- ---------------- ----------- -------------- ---------------- ----------- ---------------- -------------- ----------- ------- ----- ------ ----- ------ -------
  **Characteristics**    *N*             **%**            *N*         **%**                           *N*         \%               *N*            \%                  *N*   \%     *N*   \%     

  **Age (years)**        63.02 ± 8.566   56.30 ± 12.803   **0.000**   59.96 ± 8.41   59.52 ± 10.044   0.742       60.92 ± 10.008   62.24 ± 8.88   0.412                                         

  **Sex**                                                                                                                                                                                       

    **Female**           13              10.3             13          10.3           1.000            20          20.0             22             22.0        0.728   16    22.9   17    22.9   1.000

    **Male**             113             89.7             113         89.7           80               80.0        78               78.0           54          77.1    54    77.1                

  **Tobacco smoking**                                                                                                                                                                           

    **Never**            7               5.5              7           5.5            0.944            7           7.0              8              8.0         0.943   7     10.0   7     10.0   1.000

    **\<20 PPY**         20              15.9             22          17.5           22               22.0        23               23.0           12          17.1    12    17.1                

    **\>20 PPY**         99              78.6             97          77.0           71               71.0        69               69.0           51          72.9    51    72.9                

    **Missing**          0               0                0           0              0                0           0                0              0           0       0     0                   

  **Alcohol drinking**                                                                                                                                                                          

    **Never**            53              42.1             51          40.5           0.904            26          26.0             27             27.0        0.985   23    32.9   23    32.9   1.000

    **\<14 SDU/week**    28              22.2             31          24.6           30               30.0        30               30.0           19          27.1    19    27.1                

    **\>14 SDU/week**    45              35.7             44          34.9           44               44.0        43               43.0           28          40.0    28    40.0                

    **Missing**          0               0                0           0              0                0           0                0              0           0       0     0                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*p*-values related to controls. Statistically significant results in bold. PPY: Tobacco packs per year. SDU: Standard unit of alcohol per week.
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###### 

Statistically significant SNPs in laryngeal cancer.

  SNPs                   Genotype   Larynx   Control   *p*-Value \*   OR (CI 95%)                              
  ---------------------- ---------- -------- --------- -------------- ------------- -------------------------- ------
  ***TP53* rs1042522**   GG         61       48.4      62             49.2          Ref.                       1.00
  GC                     54         42.9     37        29.4           0.165         1.505 (0.846--2.677)       
  CC                     11         8.7      27        21.4           **0.008**     **0.319 (0.136--0.745)**   
  Recessive              GG+GC      115      91.3      99             78.6          Ref.                       1.00
  CC                     11         8.7      27        21.4           **0.002**     **0.268 (0.119--0.607)**   
  Dominant               GG         61       48.4      62             49.2          Ref.                       1.00
  GC+CC                  65         51.6     64        50.8           0.596         0.986 (0.587--1.654)       
  ***MDM2* rs2279744**   TT         44       34.9      62             49.2          Ref.                       1.00
  TG                     57         45.2     53        42.1           0.279         1.364 (0.778--2.392)       
  GG                     25         19.8     11        8.7            **0.015**     **2.826 (1.219--6.552)**   
  Recessive              TT+TG      101      80.2      115            91.3          Ref.                       1.00
  GG                     25         19.8     11        8.7            **0.029**     2.413 (1.094--5.323)       
  Dominant               TT         44       34.9      62             49.2          Ref.                       1.00
  TG+GG                  82         65.1     64        50.8           0.075         1.616 (0.953--2.742)       
  ***ERCC1* rs11615**    TT         53       42.1      45             35.7          Ref.                       1.00
  TC                     67         53.2     58        46.0           0.872         0.956 (0.550--1.661)       
  CC                     6          4.8      23        18.3           **0.013**     **0.281 (0.103--0.768)**   
  Recessive              TT+TC      120      95.2      103            81.7          Ref.                       1.00
  CC                     6          4.8      23        18.3           **0.011**     **0.288 (0.110--0.751)**   
  Dominant               TT         53       42.1      45             35.7          Ref.                       1.00
  TC+CC                  73         57.9     81        64.3           0.354         0.778 (0.457--1.324)       
  ***ERCC2* rs13181**    TT         72       57.1      52             41.3          Ref.                       1.00
  TG                     46         36.5     58        46.0           0.247         0.720 (0.413--1.255)       
  GG                     8          6.3      16        12.7           **0.046**     **0.375 (0.143--0.982)**   
  Recessive              TT+TG      118      93.7      110            87.3          Ref.                       1.00
  GG                     8          6.3      16        12.7           0.079         0.433 (0.170--1.102)       
  Dominant               TT         72       57.1      52             41.3          Ref.                       1.00
  TG+GG                  54         42.9     74        58.7           0.093         0.638 (0.377--1.078)       
  ***IL6* rs1800795**    CC         43       34.1      62             50.8          Ref.                       1.00
  CG                     64         50.8     46        37.7           **0.003**     **2.471 (1.372--4.452)**   
  GG                     19         15.1     14        11.5           0.070         2.164 (0.938--4.991)       
  Recessive              CC+CG      107      84.9      108            88.5          Ref.                       1.00
  GG                     19         15.1     14        11.5           0.444         1.351 (0.625--2.921)       
  Dominant               CC         43       34.1      62             50.8          Ref.                       1.00
  CG+GG                  83         65.9     60        49.2           **0.002**     **2.394 (1.376--4.163)**   
  ***NRF2* rs1303586**   GG         109      87.2      95             76.0          Ref.                       1.00
  GA                     14         11.2     29        23.2           **0.019**     **0.424 (0.207--0.869)**   
  AA                     2          1.6      1         0.8            0.520         2.235 (0.193--25.903)      
  Recessive              GG+GA      123      98.4      124            99.2          Ref.                       1.00
  AA                     2          1.6      1         0.8            0.444         2.600 (0.225--30.064)      
  Dominant               GG         109      87.2      95             76.0          Ref.                       1.00
  GA+AA                  16         12.8     30        24.0           **0.035**     **0.478 (0.240--0.949)**   
  ***NRF2* rs2706110**   CC         92       73.6      72             57.1          Ref.                       1.00
  CT                     24         19.2     47        37.3           **0.005**     **0.425 (0.233--0.775)**   
  TT                     9          7.2      7         5.6            0.732         1.207 (0.411--3.541)       
  Recessive              CC+CT      116      92.8      119            94.4          Ref.                       1.00
  TT                     9          7.2      7         5.6            0.403         1.574 (0.544--4.560)       
  Dominant               CC         92       73.6      72             57.1          Ref.                       1.00
  CT+TT                  33         26.4     54        42.9           **0.020**     **0.518 (0.299--0.900)**   

\* *p*-values adjusted by age. Statistically significant results in bold.

cancers-11-00493-t003_Table 3

###### 

Statistically significant SNPs in oral cavity carcinoma.

  SNPs                   Genotype   Oral Cavity   Control   *p*-Value   OR (CI 95%)                              
  ---------------------- ---------- ------------- --------- ----------- ------------- -------------------------- ------
  ***IL2* rs2069762**    **TT**     **43**        61.4      31          44.3          /                          1.00
  TG                     22         31.4          27        38.6        0.152         0.587 (0.284--1.217)       
  GG                     5          7.1           12        17.1        **0.039**     **0.300 (0.096--0.940)**   
  Recessive              TT+TG      65            92.9      58          82.9          /                          1.00
  GG                     5          7.1           12        17.1        0.078         0.372 (0.124--1.119)       
  Dominant               TT         43            61.4      31          44.3          /                          1.00
  TG+GG                  27         38.6          39        55.7        **0.043**     **0.499 (0.254--0.979)**   
  ***IL6* rs1800795**    CC         25            35.7      39          55.7          /                          1.00
  CG                     33         47.1          23        32.9        **0.031**     **2.238 (1.077--4.653)**   
  GG                     12         17.1          8         11.4        0.104         2.340 (0.839--6.528)       
  Recessive              CC+CG      58            82.9      62          88.6          /                          1.00
  GG                     12         17.1          8         11.4        0.337         1.603 (0.612--4.203)       
  Dominant               CC         25            35.7      39          55.7          /                          1.00
  CG+GG                  45         64.3          31        44.3        **0.018**     **2.265 (1.148--4.467)**   
  ***BCL2* rs2279115**   CC         13            18.6      27          38.6          /                          1.00
  CA                     43         61.4          30        42.9        **0.008**     **2.977 (1.325--6.688)**   
  AA                     14         20.0          13        18.6        0.116         2.237 (0.820--6.103)       
  Recessive              CC+CA      56            80.0      57          81.4          /                          1.00
  AA                     14         20.0          13        18.6        0.830         1.096 (0.473--2.540)       
  Dominant               CC         13            18.6      27          38.6          /                          1.00
  CA+AA                  57         81.4          43        61.4        **0.010**     **2.753 (1.273--5.952)**   

Statistically significant results in bold.
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###### 

Statistically significant SNPs in pharyngeal cancer.

  SNPs                   Genotype   Pharynx   Control   *p*-Value   OR (CI 95%)                              
  ---------------------- ---------- --------- --------- ----------- ------------- -------------------------- ------
  ***TP53* rs1042522**   GG         53        53.0      47          47.0          Ref.                       1.00
  GC                     44         44.0      33        33.0        0.583         1.182 (0.650--2.151)       
  CC                     3          3.0       20        20.0        **0.002**     **0.133 (0.037--0.476)**   
  Recessive              GG+GC      97        97.0      80          80.0          Ref.                       1.00
  CC                     3          3.0       20        20.0        **0.001**     **0.124 (0.035--0.431)**   
  Dominant               GG         53        53.0      47          47.0          Ref.                       1.00
  GC+CC                  47         47.0      53        53.0        0.396         0.786 (0.451--1.370)       
  ***NRF2* rs2706110**   CC         68        68.0      54          54.0          Ref.                       1.00
  CT                     25         25.0      41        41.0        **0.020**     **0.484 (0.262--0.893)**   
  TT                     7          7.0       5         5.0         0.863         1.112 (0.334--3.698)       
  Recessive              CC+CT      93        93.0      95          95.0          Ref.                       1.00
  TT                     7          7.0       5         5.0         0.553         1.430 (0.438--4.667)       
  Dominant               CC         68        68.0      54          54.0          Ref.                       1.00
  CT+TT                  32         32.0      46        46.0        **0.043**     **0.552 (0.311--0.982)**   

Statistically significant results in bold.

cancers-11-00493-t005_Table 5

###### 

SNPs selected in the study. Candidate SNPs were selected in oncogenes and tumour suppressor genes, DNA repair (either BER, NER and DSB), inflammatory, apoptotic and carcinogen metabolism genes, as described in Material and Methods.

  ----------------------------------------------------------------------------------------------------------
  FUNCTION                                    GENE            RS                 ID              Change
  ------------------------------------------- --------------- ------------------ --------------- -----------
  Oncogenes and tumour suppressor genes       *TP53*          1042522            C_2403545_10    Pro72Arg

  *MDM2*                                      2279744         PCR-RFLP           -410T\>G        

  *KRAS-LC6*                                  61764370        PCR-custom probe   3'-UTR          

  *EGFR*                                      2227983         C_16170352_20      Lys521Arg       

  Base excision repair (BER)                  *XRCC1*         25487              C_622564_10     Gln399Arg

  1799782                                     C_11463404_10   Arg194Trp                          

  *APEX*                                      1130409         C_8921503_10       Asp148Glu       

  Nucleotide excision repair (NER)            *ERCC2(XPD)*    13181              C_3145033_10    Lys751Gln

  *ERCC1*                                     11615           C_2532959_10       Asn118Asn       

  *XPC*                                       2228000         C_16018061_10      Ala499Val       

  Double-strand break repair genes (DSB)      *XRCC3*         861539             C_8901525_10    Thr241Met

  1799794                                     C_2983904_10    -316A\>G                           

  *KU70*                                      2267437         C_15872242_20      -731C\>G        

  Inflammatory genes                          *IL1B*          16944              C_1839943_10    -511T\>C

  *IL2*                                       2069762         C_15859930_10      -330T\>G        

  *IL6*                                       1800795         C_1839697_20       -174C\>G        

  *IL10*                                      1800872         C_1747363_10       -592C\>A        

  *TNFA*                                      361525          C_2215707_10       -238A\>C        

  Apoptotic genes                             *NOD2*          2066844            C_11717468_20   Arg702Trp

  2066845                                     C_11717466_20   Arg908Gly                          

  *BAX*                                       4645878         C_27848291_10      -248G\>A        

  *BCL2*                                      2279115         C_3044428_30       -938C\>A        

  Carcinogen metabolism/antioxidative genes   *CYP3A5*        776746             C_26201809_30   6986A\>G

  *GSTP1*                                     1695            C_3237198_20       Ile105Val       

  *GSTT1*                                     N/A             PCR                Null/present    

  *GSTM1*                                     N/A             PCR                Null/present    

  *NFE2L2*\                                   13035806        C_11745134_10      3'-UTR          
  *(NRF2)*                                                                                       

  2706110                                     C_11745133_10   3'-UTR                             

  *KEAP1*                                     1048290         C_9323035_10       Leu471Leu       
  ----------------------------------------------------------------------------------------------------------
